Loading stock data…
SNDX
$19.11-2.32 (-10.83%)
Market ClosedLast close May 1
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Syndax Pharmaceuticals, Inc. in the Healthcare sector is trading at $19.11. The stock is currently 25% below its 52-week high of $25.59, remaining 3.7% above its 200-day moving average. Technical signals show oversold RSI of 21 and bearish MACD signal, explaining why SNDX maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 21) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$19.11
Potential Upside
5%
Whystock Fair Value$20.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$39.67+107.6%
Range$28.00 – $57.00
Fundamentals
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R ac...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.95B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.41
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-518.32%
Volume
Today's trading volume
4.67M
Recent News
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...
Syndax Pharmaceuticals Inc (SNDX) reports significant revenue increases and strategic advancements in the competitive menin inhibitor market.
Syndax Pharmaceuticals Q1 Earnings Call Highlights
Syndax Pharmaceuticals (NASDAQ:SNDX) reported first-quarter 2026 results highlighting more than $100 million in combined net sales for its two commercial products, Revuforj and Niktimvo, as the company emphasized continued uptake, expanding treatment patterns, and multiple upcoming clinical data rea
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +17.95% and -7.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.